FAQ on Soligenix Inc.'s Progress in Rare Disease Therapeutics and HyBryte(TM) Platform

What is Soligenix Inc. known for?

Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, including its HyBryte(TM) platform for cutaneous T-cell lymphoma.

Why is Soligenix’s work on rare diseases significant?

Over 30 million Americans live with rare conditions, many lacking FDA-approved therapies, making Soligenix’s efforts to develop treatments like HyBryte(TM) crucial for underserved populations, especially aging adults.

What is HyBryte(TM) and what does it target?

HyBryte(TM) is Soligenix’s novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.

How far along is Soligenix in developing HyBryte(TM)?

Soligenix has successfully completed the second Phase 3 study of HyBryte(TM) and is moving toward seeking regulatory approvals to support potential commercialization worldwide.

What other diseases is Soligenix targeting?

Beyond CTCL, Soligenix is expanding synthetic hypericin into psoriasis, developing dusquetide for inflammatory diseases, and working on vaccines for ricin toxin, filoviruses, and COVID-19.

How is Soligenix’s Public Health Solutions business segment funded?

This segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

Where can I find more information about Soligenix Inc.?

For further information, visit the company’s website at www.Soligenix.com or the latest news and updates at https://ibn.fm/SNGX.

What is the significance of Soligenix’s domestic manufacturing of HyBryte’s active ingredient?

Successful domestic manufacturing of HyBryte’s active ingredient advances Soligenix’s mission to serve the underserved demographic of aging adults with rare diseases with innovative, U.S.-based therapies.